Li W, Stall A, Shivers S C, Lin J, Haddad F, Messina J, Glass L F, Lyman G, Reintgen D S
Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, Florida 33612, USA.
Ann Surg. 2000 Jun;231(6):795-803. doi: 10.1097/00000658-200006000-00003.
To determine the clinical significance of a molecular assay based on the reverse transcriptase polymerase chain reaction (RT-PCR) for the presence of micrometastatic melanoma cells in sentinel lymph nodes (SLNs).
Routine histologic examination of lymph nodes often underestimates the presence of micrometastatic disease. The authors have previously shown that an RT-PCR assay designed to detect melanocyte-specific expression of the tyrosinase gene could be used to define a population of patients at higher risk for both recurrence and death compared with routine hematoxylin and eosin (H&E) histology. In this study, the authors used the tyrosinase RT-PCR assay in a patient population examined by a more detailed histologic analysis, including S-100 immunohistochemistry.
Patients underwent lymphatic mapping and SLN biopsy. SLN specimens were bivalved, and half of each specimen was serially sectioned and examined by routine H&E histology and S-100 immunohistochemistry. The other half of each specimen was analyzed by a nested RT-PCR assay.
Hematoxylin and eosin histology detected metastatic disease in 36 (16%) of the 233 patients tested. S-100 immunohistochemistry detected micrometastatic disease in another 16 patients, and 114 (63%) of 181 patients with histology-negative nodes had positive findings on RT-PCR. There were significant differences between PCR-positive and PCR-negative patient groups in Breslow thickness, Clark level, and the presence of ulceration of the primary tumor, factors that have been shown to correlate with recurrence and survival.
These results suggest that RT-PCR can increase the sensitivity of detection of metastatic melanoma cells in SLNs over the current standard methods, including H&E histology and S-100 immunohistochemistry. Further long-term follow-up is needed to detect actual differences in recurrence and overall survival.
确定基于逆转录酶聚合酶链反应(RT-PCR)的分子检测对于前哨淋巴结(SLN)中微转移黑色素瘤细胞存在情况的临床意义。
淋巴结的常规组织学检查常常低估微转移疾病的存在。作者先前已表明,一种旨在检测酪氨酸酶基因黑色素细胞特异性表达的RT-PCR检测方法,与常规苏木精和伊红(H&E)组织学相比,可用于确定复发和死亡风险更高的患者群体。在本研究中,作者在通过更详细的组织学分析(包括S-100免疫组织化学)检查的患者群体中使用了酪氨酸酶RT-PCR检测方法。
患者接受淋巴管造影和SLN活检。将SLN标本切成两半,每个标本的一半进行连续切片,并通过常规H&E组织学和S-100免疫组织化学检查。每个标本的另一半通过巢式RT-PCR检测进行分析。
在233例接受检测的患者中,H&E组织学在36例(16%)中检测到转移性疾病。S-100免疫组织化学在另外16例患者中检测到微转移疾病,在181例组织学阴性淋巴结的患者中,114例(63%)RT-PCR检测结果为阳性。PCR阳性和PCR阴性患者组在Breslow厚度、Clark分级以及原发性肿瘤溃疡的存在情况方面存在显著差异,这些因素已被证明与复发和生存相关。
这些结果表明,与包括H&E组织学和S-100免疫组织化学在内的当前标准方法相比,RT-PCR可提高SLN中转移性黑色素瘤细胞的检测灵敏度。需要进一步进行长期随访以检测复发和总生存方面的实际差异。